Trials / Withdrawn
WithdrawnNCT04017208
A Study to Assess ASP2713 in Healthy Subjects
A Phase 1 Single Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2713 in Healthy Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety and tolerability of ASP2713 in healthy participants. The study will also evaluate the pharmacokinetics and pharmacodynamics of ASP2713.
Detailed description
This study will consist of a screening period, a single residential period of 10 days/9 nights and a safety follow up period. Subjects will be randomized to either ASP2713 or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP2713 | Administered intravenously |
| DRUG | placebo | Administered intravenously |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2020-08-01
- Completion
- 2020-08-01
- First posted
- 2019-07-12
- Last updated
- 2024-10-16
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04017208. Inclusion in this directory is not an endorsement.